Physician Views: Evaluating the Launch of Novartis' Cosentyx for Psoriasis
Approved in both the US and EU at the beginning of the year, Novartis' first-to-market IL-17 inhibitor Cosentyx could be the most effective psoriasis treatment available, suggest key opinion leaders recently interviewed by FirstWord.
Novartis certainly appears confident in the commercial outlook for Cosentyx, indicating at an investor presentation last week that the monoclonal antibody could generate peak annual sales of between $4 billion and $5 billion (ViewPoints: As dust settles on brodalumab setback, Novartis touts Cosentyx as game-changer in psoriasis).
Currently being assessed in Phase III studies, Eli Lilly's competing IL-17 inhibitor ixekizumab will provide a competitive threat at some point in the future, as will a raft of other, earlier development-stage therapies assessed in FirstWord's forthcoming report on the psoriasis market.
It remains unclear as to whether a recently announced safety concern for another IL-17 inhibitor – AstraZeneca's brodalumab, which may or may not reach the market – will prove beneficial to Cosentyx or will heighten caution towards the class until long-term safety data is available.
With Cosentyx now available for some months, and with the product poised to be one of the biggest new drug approvals of 2015, FirstWord is polling dermatologists with the following questions...
Novartis certainly appears confident in the commercial outlook for Cosentyx, indicating at an investor presentation last week that the monoclonal antibody could generate peak annual sales of between $4 billion and $5 billion (ViewPoints: As dust settles on brodalumab setback, Novartis touts Cosentyx as game-changer in psoriasis).
Currently being assessed in Phase III studies, Eli Lilly's competing IL-17 inhibitor ixekizumab will provide a competitive threat at some point in the future, as will a raft of other, earlier development-stage therapies assessed in FirstWord's forthcoming report on the psoriasis market.
It remains unclear as to whether a recently announced safety concern for another IL-17 inhibitor – AstraZeneca's brodalumab, which may or may not reach the market – will prove beneficial to Cosentyx or will heighten caution towards the class until long-term safety data is available.
With Cosentyx now available for some months, and with the product poised to be one of the biggest new drug approvals of 2015, FirstWord is polling dermatologists with the following questions...
- In your experience with Cosentyx (secukinumab) to date, how would you characterise efficacy?
- In your experience with Cosentyx to date, how would you characterise safety/tolerability?
- Over the next 12 months, how do you expect your usage of Cosentyx to change?
- Have side-effect concerns with another development-stage anti 1L-17 antibody (brodalumab) had/will have any adverse impact on your usage of Cosentyx?
- In 12 months' time, in what percentage of patients would you expect to be using Cosentyx as the first-line biologic therapy?
